Recs

1

Medivation Shares Popped: What You Need to Know

By Cindy Johnson | More Articles
April 1, 2011 | Comments (2)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Medivation (Nasdaq: MDVN  ) popped 11% in intraday trading today after announcing it initiated a phase 2 clinical trial.

So what: Medivation is developing a drug called MDV3100 for the early treatment of advanced prostate cancer. Currently, there are limited options for treatment of this disease, with Dendreon's (Nasdaq: DNDN  ) Provenge as the established competitor. 

Now what: MDV3100 is already in phase 3 testing for advanced prostrate cancer. The new trial announced today should determine whether it is effective earlier in the course of the disease, which would open up a larger market. Johnson & Johnson (NYSE: JNJ  ) , Exelixis (Nasdaq: EXEL  ) OncoGenex Pharmaceuticals (Nasdaq: OGXI  ) and its partner Teva Pharmaceuticals (Nasdaq: TEVA  ) are also testing drugs to treat the disease, with J&J appearing to be ahead of the others.

Interested in more info on Medivation? Add it to your watchlist by clicking here.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Cindy Johnson does not own shares of any company named above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 01, 2011, at 6:16 PM, joe2dmoon wrote:

    And all these companies' products are still years away from approval; let alone competing with DNDN. J&J's aber. acetate caused over 12% abnormal heart function in patients in clinical trial. Fda will ask for more studies on this side effect before any final considerations.

  • Report this Comment On April 04, 2011, at 12:03 PM, expatriot08 wrote:

    I guess the fool sold their shares of EXEL. Here's to hoping they got out early!

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1468856, ~/Articles/ArticleHandler.aspx, 5/26/2012 7:58:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
MDVN $87.38 Down -1.54 -1.73%
Medivation, Inc. CAPS Rating: **
OGXI $13.02 Down -0.09 -0.69%
OncoGenex Pharmace… CAPS Rating: **
TEVA $38.61 Down -0.08 -0.21%
Teva Pharmaceutica… CAPS Rating: *****
JNJ $62.51 Down -0.59 -0.94%
Johnson & Johnson CAPS Rating: *****
DNDN $7.11 Down -0.11 -1.52%
Dendreon Corp CAPS Rating: **
EXEL $4.61 Up +0.03 +0.66%
Exelixis CAPS Rating: *****

Advertisement